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The following abbreviations are adopted in this study: 
AB Alcian blue 
ANOVA Analysis of variance 
BM Boehringer Mannheim 
CPC Cetypyridinium chloride 
CS Chondroitin sulphate 
CTAB Cetyl-trimethyl ammonium bromide 
DMB Dimethybnethylene blue 
DS Dematan sulphate 
GAG Glycosaminoglycan 
HPLC High performance liquid chromatography 
HS Heparan sulphate 
KS Keratan sulphate 
MPS Mucopolysaccharidoses 
SD Standard deviation 
TLC Thin layer chromatography 
Summary 
This study was to develop an automated quantitative screening method for 
m u c o p o l y s a c c h a r i d o s e s ( M P S ) . In principle, urinaiy gIycosaminoglycans (GAGs) react 
with Dimethyhnethylene blue ^ M B ) dye to form a colour complex. The change in 
absorbance due to a decrease of free dye concentration is monitored in an automated 
centrifiigaI analyzer. Absorbance change is related to the concentration ofurinary GAG. 
The spectra ofDMB dye, DMB-GAG products were studied. Pure DMB had two 
absorption maxima: 593nm and 649m while the DMB-GAG complexes had absorption 
marima varying between 528-543nm. Quantitation of GAG concentration can be 
automated by monitoring the absorbance at 593誰 in a Cobas Bio Centrifogal Anatyzer. 
The DMB dye and the DMB-GAG complexes were stable for at least 300 seconds. The 
lowest detection Hmit was found to be 0.8mg/L aiul the linearity range was up to 70mg/L 
usingaDMB concentration of35 i^moVL. Sensitivity analysis gave an absorbance change 
ofo.285A per ug ofGAG in the reaction ceU. Albumin and haemoglobin did not interfere 
xvith this assay up to 5g/L and 5g/L, respectively. This assay correlated weU with the 
CPC/Carbazole method(p=0.929), Between-batch coefficient of variation ranged from 
2.4% to 6,5%. This method required a sample volume of20^d and 5 minutes to assay for a 
batch of20 samples and controls. Age specific reference range of urinary GAG/creatinine 
ratio for Hong Kong Chinese population was estabHshed from 545 healthy subjects with 
age ranging from 1 day to 70 years old. No previous reference range for Chinese subjects 
was reported in the literature and this was the first one. The urinary GAG/creatinine ratio 
was not significantly different between the two sexes. However，it was age dependent. A 
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group of295 handicapped, mentally retarded patients were studied and 35% ofthem had 
elevated urinary GAG/creatinine above the 95% upper reference value. 
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1. Introduction 
MPS are a group of inherited diseases of connective tissue metabolism. The 
diseases are characterized by an increased urinary excretion of GAG. Many screening and 
confirmation tests are available. However, current methods used are technically 
cumbersome and labour-intensive. Simple dye-binding screening methods using DMB has 
been published(l,2,3). These DMB assays measured the DMB-GAG product using 
absorbance values at about 530nm. Nevertheless, the absorption maxima ofthe complexes 
varied between 52S-541nm and the molar absorptivity of the complexes difFered(4). Thus 
measurement ofproducts at one wavelength could lead to inaccurate results depending on 
the relative composition of different GAGs in the samples. 
A recent study between interaction of the dye with GAGs has shown possible 
sohition to this problem(4). Pure DMB dye was shown to have two absorption peaks. The 
alternative solution was to measure the decrease in absorbance at either one of the two 
peaks rather than the increase in absorbance at the product peak. This study attempts to 
automate the measurement of urinary GAGs in a centrifugal anatyzer based on the 
decrease of the absorbance due to the dye. 
La order to adapt this new method into routine use, reference range for urinary 
GAG has to be established. Reference ranges of urinary GAGs have been reported in many 
studies for westem populations(3-6), but there is none for Asian. Therefore，this study 
intends to estabHsh a reference range for local Hong Kong Chinese population. 
Furthermore, as part of a study on mentaUy retarded patients Uving in a care home, urinary 
GAG excretion in this group of patients was measured. 
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2. Literature Review 
MPS are a group of genetic disorders characterized by the accumulation of 
mucopolysaccharide (glycosaminoglycan is the preferred term) in various tissues. Short 
Hfe expectancy and mental retardation are found in severe forms. Presently no specific 
th^apy is available，but supportive treatment can greatly improve the quality of life of 
patients. Thus, early diagnosis is helpfiil. It is important to design methods for its 
detection. In patients with MPS, increased urinary GAGs excretion is a characteristic 
finding. Screening methods are based on the measurement of urinary GAGs. 
2.1 Properties of GAGs 
GAGs are long，linear molecules made up of repeating disaccharide units, each of 
which contains a hexuronic acid (P-D-glucuronic or L4duronic acid) and an amino sugar 
(glucosamine or galactosamineXsee Table 2.1). Li keratan sulphate, galactose replaces the 
hexuronic acid. Most of the GAGs are highly sulphated and acetylated They are found in 
relatively large amounts in skin, cartilage, bone, comea, Wood vessels, heart valves and 
tendons. Smaller quantities occur in Uver, brain, leukocytes and mast ceUs(7). 
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Table 2.1~The disaccharide units of different GAGs 
GAG Disaccharide Unit 
Heparan sulphate iduronic acid/'glucuronic acid and glucosamine 
Dennatan sulphate iduronic acidy"glucuronic acid and galactosamine 
Keratan sulphate galactose and glucosamine 
Chondroitin sulphate glucuronic acid and galactosamine 
Hyaluronic acid glucuronic acid and glucosamine 
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2.1.1 FUNCTION OF GAGs 
The major structural component ofcartilage, proteoglycans are made up ofGAGs 
and protein core(7). They confer resiUency tQ cartilage. It has been suggested that one role 
of proteoglycans is to prevent calcification of cartilage. Proteoglycans are found to be 
associated with fibers of considerable tensional strength in tissues such as tendoB, deep 
dermis and heart valve. GAGs may have an important lubricative functioninjoint fluid. 
2.1.2 METABOLKM OF GAGs 
ZLZ1 Synthesis 
The sulphated GAGs in cartilage and connective tissue occur primarily as 
polysaccharides Hnked to protein. In cartilage proteoglycan biosynthesis, GAG chain 
initiation is a key point m regulation (7). It is dependent on the availabiHty ofcore protein 
sites for chain initiation. A branching enzyme is needed to initiate a GAG branch from the 
core. Agents which suppress the level of activity of the branching enzyme would inhibit 





The GAGs are degraded primarily by lysosomal enzymes that sequentially cleave a 
monosaccharide or sulphate from the non-reducing terminus of the mucopolysaccharides 
chain. At least eleven enzymes including four glycosidases, five sulphatases and one 
nonhydrolytic transferase (9) are required to degrade the mucopolysaccharide chain (8). 
Defects ofany one of these enzymes interrupt the sequence ofdegradation, resulting in the 
mucopolysaccharides chain being resistant to further cleavage by the enzymes. It wiB 
result in the accumulation of GAGs in the lysosomes. Figures 2.1, 22, 2.3 depict the 
enzymology oflysosomal degradation of dermatan sulphate, heparan sulphate and keratan 
sulphate and the enzyme deficiencies in the MPS. Table 2.2 summarizes the enzyme 
deficiencies reported in MPS and the major storage substances reported for theirs disorder 
based on the McKusick's and Neufeld Classification (9). 
There are two types of lysosomal glycosidases: exoglycosidases and 
endoglycosidases. Exoglycosidases hydrolyze Hnkages only at the non-reducing terminus 
of the GAGs. EndogIycosidases cleave interchain linkages. The missing enzymes that lead 
to MPS are exoglycosidases. Li some tissues, GAGs can undergo Umited degradation by 
endoglycosidases. The incompletely degraded GAG fragments then accumulate in the 
tissues or are excreted in the urine. 
PAGE 7 
CHjOH C00' CH,0S03' 
C u j C X ^ j C > ^ ^ ^ ^ X _ i 5 x 
OSO," NHSO; NHCOCHj OSO； N P 8 Z I 
>^/ iduronat*-2-ouX|diat* Aulphatasa (Buntar) 
CH,OH C00' CH^ 0S03" 
< ^ X X X ^ / > ^ _ ^ i 5 x 
^ NHSO; kHCOCH3 6S0; MPS I 
\ , lduroni>dMe (Burl«r) 
CHjOH COO" CH^ 0S03' 
C U _ 0 ~ ^ L _ ^ \ 
NHSO； MCOCH, OSO； 
. / h ^ a r a n H-sulphatas^ MPSIIIA 
c ^ H COO- cH,oso3- (Saaf i l ipo K) 
cyj:y-^^y^j^. 
NH, NKCOCH3 6S0; 
acflityl CoA: glnoosamiM MPS IIIC 
( ： 么 广 鄉 气 ？ ？ 无 一 两 0 3 - � S a n f i i i p o C) 
C w / > ^ ~ ^ 3 L i ! ^ � � 
NHCOCE, NHCOCH^  OSO， 
cHr^acetlglucoseminidase ®® IZIB 
^ coo- ™ 3 - {Sanfil ipo B) 
0 ^ � L ^ < ^ � � 
NHCOCH, OSO, 
N/ p-glueuroaida«a ^^ 对工 
^ o 3 - <siy) 
0 _ ^ ^ \ NHCOCEj 0S0\ 
V-tto*tylglTUSosamina 勘总 I l ID 
6-Eulphaf . u l p h a t a s . t <Sanfillpo D) 
C u ^ . 
NHCOCE， QSO； 
Figures 2.1~"Degradation of heparan sulphate and the diseases 
caused by deficiency of specific enzymes 
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Figures 2.3~Degradation of keratan sulphate and the diseases 
caused by deficiency of specific enzymes 
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TABLE 2.2—The classification, enzyme deficiency and urinary GAG pattern in different 
kindsoftheMPS(9) 
Number Eponvm Enzvme Deficiency Urinarv GAGs 
MPS I-H~~ Hurler a-L-Iduronidase Dermatan sulphate, 
heparan sulphate 
MPS I-H/S~^Hurler/Scheie a-L4duronidase Dermatan sulphate, 
heparan sulphate 
M P S I - S ~ Scheie a-L-Iduronidase Dermatan sulphate, 
heparan sulphate 
MPS II-A Hunter, severe Iduronate sulphatase Dermatan sulphate, 
heparan sulphate 
MPS n-B Hunter, mild Iduronate sulphatase Dermatan sulphate, 
heparan sulphate 
MPS III"A ~ Sanfilippo A Heparan N-sulphatase Heparan sulphate 
MPS III-B Sanfilippo B a-N- Heparan sulphate 
acetylglucosaminidase 
MPS ffl-C Sanfilippo C Acetyl coenzyme A: a- Heparan sulphate 
glucosamine-N-
acetyltransferase 
MPS ni-D SanfiUppo D N-acetyl-a-glucosamine- Heparansulphate 
6-sulphatase 
MPS rV-A~~Morquio A N-acetylgalactosamine-6- Keratan sulphate 
sulphatase 
MPS F/-B Morquio B p-galactosidase Keratan sulphate 
MPSVI Maroteaux-Lamy N-acetylgalactoasamine- Dermatan sulphate 
4-sulphatase 
(arylsulphatase B) 






MPS are a group ofinherited lysosomal storage diseases caused by deficiency of 
specific lysosomal enzymes which are needed for the stepwise degradation of GAGs (9). 
In 1917, Hunter (10) presented a description of two brothers who appeared to have had 
the sex-Unked MPS which bear his name. Jn 1919，Gertrude Hurler (11) described two 
unrelated boys with coarse facial features, multiple skeletal abnormalities, comeal 
clouding, hepatosplenomagaly and cardiac involvement TMs detailed description served 
as the prototype for the descriptions of MPS that followed. In 1952, Brante (12) 
introduced the term ‘mucopolysaccharidoses’ based on the finding of excessive GAG 
accumulation in the liver of a patient with the Hurler syndrome. In 1957，Dorfinan and 
Lorincz(13) discovered the excessive secretion of GAG in the urine of Hurler syndrome. 
hi 1965，McKusick (14) systematized the classification ofthe MPS based on the types of 
GAGs excreted in the urine, mode ofinheritance and ciinical features_ 
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2,2.1 CLWICAL PRESENTATION AND GENETICS OF MPS 
2,2.1�1 Clinical manifestation 
MPS are progressive in nature and involve multiple tissues and organs. The MPS 
share numy clinical features, including neurological, visceral md skeletal disorders. 
Organomegafy, dysostosis multiplex and abnormal facies are some common 
characteristics. Hearing，vision, cardiovascular fonction andjoint mobUity may be affected. 
Table 2.3 summaries the cMcal manifestations, and onset of the diseases (9). 
Z2J,2 Genetics and incidmces 
The incidence of MPS are rare. MPS type m has the highest incidence(l in 
24000). Most ofthem are inherited as autosomal recessive. MPS type H is an exception, 
which is sex-linked. The genetics and incidences ofthe diseases are Hsted in the table 2.4. 
2,2.2 Treatmettt 
Presently no specific treatment is available. Management of MPS patients consists 
of supportive care and treatment of complication. Jn diseases QAPS IS and MPS VI) 
where Ufe expectancy and intelUgence are not affected，management of the cUnical 
symptoms seems indicated such as treatment of the corneal clouding, the aortic valve 
disease (7,15). 
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In severe diseases (e.g. MPS H), therapeutic trials with 'correcting factors'(shown 
to be lysosomal enzymes) (7), fibroblast transplantation (16), amnion transplantation (17) 
and bone marrow transplantation have been performed. Bone marrow 
transplantation(BMT) is promising. There are a number of reports evaluating the efficacy 
of BMT for the treatment of MPS: MPSI (18-20), MPSII (21), MPSVI (22,23). 
Treatment by gene transfer is under research (9). 
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TABLE 2.3~~The cUnical manifestations，and onset of the diseases in different kinds of 
theMPS(7,9,24) 
Number Qinical manifestations Year of onset .  
MPSlH Comeal clouding, dysostosis 6-12 months, death usualiy before 
multiplex, organomegaly, heart age 10 
disease，mental retardation, death 
in childhood 
MPSlS Corneal clouding, stiffjoints’ 5-15 years 
normal intelligence and life span 
MPSlH/S Phenotype intermediate between 2-4 years, survival into 20s 
lH and lS 
MPSn(severe) Dysostosis multiplex, 2-4 years，death by 10-15 years 
organomegaly, no comeal 
clouding, mental retardation 
l^SII(mild) “ Normal intelUgence, short stature first decade, survival to 2Qs to 6Qs 
MPSmA Profound metal deterioration, 2-6 years, death at end of puberty 
hyperactivity，relatively mild 
somatic manifestations 
MPSmB CUnicaUy indistinguishable from onset later than HIA, longer 
MPSIIIA survival than fflA (24) 
MPSIIIC Phenotype similar to IIIA 
MPSTTTD Phenotype similar to IIIA 
MPSWA Distinctive skeletal abnormalities, 1-3 years (9), death by 20-40 years 
comeal clouding，odontoid (7) 
hypoplasia, milder forms known to 
exist 
MPSIVB Short stature, comeal clouding, onset later than IVA (9) 
mild dysostosis multiplex, 
prominence oflower face，pectus 
carinatum, hip deformity, normal 
intelligence 
MPSVI Dysostosis multiplex, corneal 4 years, death in 20s 
clouding, normal intelligence, 
milder forms known to exist 
MPSVn Dysostosis multiplex, 1-2 years 
hepatosplenomegaly, wide 
spectrum of severity 
PAGE 15 
TABLE 2.4—The genetics and incidences ofthe MPS(15,25-29) 
Number Incidence Genetics/transmission Reference 
MPSlH 1 in 100,000 Homozygous for MPSlH (25) 
gene, 
autosomal recessive 
MPSlS 1 in 500,000 HomozygousforMPSlS ^ 1 ^ 
gene, 
autosomal recessive 
MPSlH/S 1 in 115,000 Genetic compound for (15) 
MPSlHand lSgenes, 
autosomal recessive 
MPSn(severe"^"1 in 67,500 Hemizygous for X-linked (26) 
) gene, 
sex-linked 
MPSn(mild)~~1 in 67,500 Hemizygous for X-Unked (27) 
gene， 
sex-linked 
MPSIHA Homozygous for Sanfilippo A 
gene, autosomal recessive 
MPSnCB Homozygous for Sanfilippo B 
1 in 24,000 gene，autosomal recessive (27) 
MPSniC Homozygous for Sanfilippo C 
gene, autosomal recessive 
MPSnff) Homozygous for Sanfilippo D 
gene, autosomal recessive 
MPSrVA Homozygous for Morquio A 
1 in 300,000 gene, autosomal recessive (28) 
MPSrVH3 Homozygous for Morquio B 
gene autosomal recessive 
MPSVI rare, no data Homozygous for allele at M-L (26) 
locus，autosomal recessive 
MPSVn fewer than 20 cases Homozygous for mutant gene (29) 
described at P-giucuronidase locus, 
autosomal recessive 
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2.3 Laboratory tests for the diagnosis of MPS 
2.3.1 SCREENWG 
Measurement ofGAG content in urine is generaUy used as screening procedure for 
MPS. Itrfected samples should not be Msed (5). Some preservatives may interfere with the 
analyses e.g. toluene lowers the efficiency ofprecipitation methods (5). Samples are to be 
frozen solid as soon as possible after coUection. 
t3J.l Spattest 
paper spot tests are based on the interaction of urinary GAGs with a suitable 
cationic dye such as toludine blue (30)，alcian blue (AB)(31,32), azur A (33). A fixed 
volume ofurine is appUed to filter paper，dried and stained with a solution ofthe dye. Spot 
tests are easy to perform. However, they are either quaUtative or semi-quantitative oriy. 
High incidence of false-negative results was reported (5). Thus paper spot tests are not 
recommended as screening tests for MPS. 
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23.L2 Turhidity test 
It is based on the precipitation ofGAGs with acidified albumin (34,35), quaternary 
ammonium compounds such as cetyl-trimethyl ammonium bromide(CTAB) (36), 
cetypyridimum chloride(CPC) (37), and CPC citrate test (38). Precipitation of GAGs with 
CPC or CTAB is affected by ionic strength and pH (39) as well as by concentration. If 
these factors are not taken into account, urine samples may give false positive or fabe 
negative results (5). In a method described by Pennock (5)，the effects of ionic strength 
and pH could be overcome by buffering the CPC solution with citrate at pH 4.8. 
23,L3 XJronic acid-carbazole test 
Quantitative estimation is based on measurement ofhexuronic acid residues which 
all GAGs contain, except keratan sulphate. Before quantitation, it has to carried out a 
suitable GAG preparation. The preparation is to separate GAGs from other interfering 
substances and can be achieved by: dialysis (40,41); dialysis Mowed by fractionation on 
cellulose columns (42,43); precipitation with CTAB, CPC (44,45) or aminoacridine 
(46,47). The hexuronic acid in the GAGs is measured by reaction with the carbazole-
sulphuric acid (48). The hexuronic acid will react with carbazole in the presence of 
concentrated sulphuric acid to give a magenta coloured product. Quantitative 
determination ofthe hexuronic acid residues of GAGs with the carbazole-sulphuric acid 
reagent has the disadvantage that it M s to detect the keratan su^)haturia of Morquio's 
syndrome(MPS W). In addition the assay is potentiaUy dangerous，owing to the use of 
concentrated sulphuric acid. 
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2,3丄4 Dye binding 
It is based on the direct interaction of GAGs with metachromatic dyes such as 
AB(49,50) and DMB(l,51). It allows automation in routine chemical analyzers and will be 
discussed later. Gold (50) described a method based on AB for the direct measurement of 
GAGs on untreated urine samples. Recently, de Jong et al (49) described a modified AB 
method to estimate GAGs in the presence of other polyanions (52) and compared their 
method with DMB and the results were summarised on table 2.5. 
Table 2.5 Conq>arison between modified AB and DMB. 
modified AB PMB — 
Samplevolume — 180ul 5-20ul 
CV(10 runs) lJ% 4% 
Recovery(without protein) 78-95% 94-103% 
(withprotein) 76-111% 96-100% 
Correlation(non MPS) AB-1.055DMB-0.029, r=0.861 
(MPS) AB=1.126DMB+6.225, r=0.928 
Standard deviation scores 8.5 1&2 
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The DMB as$ay had a higher sensitivity and the smaUer sample volume used 
probably made it less sensitive to interfering substances. It aUo showed a better 
discriminatory power between MPS and normal urine samples. Therefore DMB assay was 
better suited for urinary screening for MPS than the AB assay. 
However, the DMB assays developed so far involved the measurement of the dye-
GAG complex. The different reaction products of the dye-GAG complex show different 
moUu: absorptivity, making spectrophotometric quantitation difficult. A recent study (4) of 
the interaction of the dye with GAG has shown possible solution to this problem by 
measuring the decrease ofthe absorbance due to the dye, not the increase of absorbance 
due to the product. 
2.4 Confirmation method 
Confirmation method can be made either by identifying the missing enzyme in 
serum or the accumulated GAGs in urine. The enzymes essential for the catabolism of 
GAGs are shown in the figures 2.1，2.2, 2.3. The accumulated GAG products in urine 
characteristic ofeach MPS are shown in table 2.2. 
2.4.1 Enzyme assay 
Enzyme assay is specific and reUable. Definitive diagnosis of the MPS is 
estabtished by enzyme assays (53,54). Samples such as cultured fibroblasts may be used 
for aU the MPS; leukocytes for most MPS; serum or plasnm for MPS ^ H, HTO and VHA. 
The enzyme assay can be performed using chromogenic, fIuorigenic or radioactive 
substrates. 
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Prenatal diagnosis is possible for aU the MPS. Samples include Mnniotic fluid, 
cultured ceUs or uncultured ceUs from amniotic fluid, chorionic villus biopsies. Carrier 
detection for the autosomal recessive MPS is possible by measuring the relevant enzyme in 
leukocytes or serum. Statistically heterozygotes show activity half of the normal level The 
wide range and the overlap between the heterozygotes and normal groups mdce 
classification ofa particular individual difficult and at times impossible. They may be used 
to determine the carrier status ofrelatives of affected patients who are at risk but are not 
practical for large scale screening. Carrier detection in sex-Unked Hunter's syndrome had 
been achieved by cloning of cultured fibroblasts (55,56) or testing hmr roots(57,58) but 
these methods are labor-intensive and costiy. 
2.4.2 Electrophoresis 
Sulphated GAGs can be separated by electrophoreas on a ceUulose acetate 
membrane in barium acetate buffer (59) or barbitone buffer (37). The separation is based 
on the differences of GAG structure. Electrophoresis in barbitone buffer cannot separate 
dennatan sulphate from chondroitin sulphates, nor heparan sulphate from keratan sulphate 
(5). However, it is a usefol method for separating galactosamine containing GAG from 
glucosamine containing GAGs. Electrophoresis in barium acetate gives good separation of 
dermatan sulphate and heparan sulphate (60) but give poor separation between keratan 
sulphate and chondroitin sulphates. 
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2,4.3 Chromatography 
TLC is used to separate the GAGs according to their solubility in different 
solvents. Many methods have been described (61,62). The problems associated with these 
methods include difficulty 'm separating dermatan sulphate (61) or keratan sulphate (62) 
from other GAGs. A method is based on the relative solubiKty of different GAGs, as their 
calcium salts, in different concentration of alcohol (63,64).This method was claimed to 
clearly separate keratan sulphate from other GAGs and was thus useful in the diagnosis of 
Morquio's disease. However, this method involves the use of running a TLC plate in six 
separate solvents in sequence. Certainly H is tedious and time-consuming. One study also 
investigated the application ofHPLC in the identificaticm and quantitation ofGAGs (65). 
PAGE 22 
2.5 Conclusion ofUterature Review 
1. Paper spot tests are quaHtative or semi-quantitative only and give high incidence of 
false-negative results (5). 
2. Quantitative determination ofthe hexuronic acid residues of GAG molecules with the 
borate-carbazole reagent fails to detect the keratan sulphaturia of Morquio's 
syndrome(MPS W), 
3. Many existing methods depend on the isolation of GAGs by precipitation with 
quaternary ammonium salts or on separation techniques such as electrophoresis (5,59) 
or TLC (61-64). These methods are technicaUy cumbersome，labour-intensive and 
require large urine specimens (1 to 10 ml). 
4. Precipitation ofGAGs with CPC or CTAB is affected by ionic strength and pH (39) as 
weU as by concentration, ffthese factors are not taken into account, urine samples may 
give false positive or false negative results (5). 
5. Enzyme assays are specific and reliable. But they are labour-intensive and not 
convenient for screening. 
6. Existing methods are not practicable for mass screening because of 
• the large sample volume required, 
• preparative isolation procedures required before quantitation, 
• interference by other negatively charged ions other than sulphated GAG in direct 
assay (50,66). 
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2.6 Choice ofmethod 
1. Knowledge ofthe urinary GAG concentration coupled with the cHnical manifestation 
can help to choose the most appropriate enzymatic assay to diagnose conclusively the 
specific type ofMPS. 
2. MPS disease is presented cUnically between 9 months and 4 years of age and detection 
ofincreased GAGs in urine may confirm the diagnosis. 
3. With the recent progress in the treatment of these disorders, earlier therapeutic 
intervention is crudal. Therefore presymptomatic diagnosis by means ofroutine mass 
screening of aU newborn infants is strong motivation. 
4. The enzymatic determinations are often tedious and expensive and must be preceded 
by the study ofGAGs excreted in urine. 
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2.7 TheprBsent study 
This study intend to investigate the spectra of the pure DMB, individual GAG 
reacting with DMB, and mixtures ofGAGs reacting with DMB. A suitable wavelength for 
the quantitation ofGAGs is to be evaluated. The peak wavelength or nearby wavelength 
ofDMB vM be used to quantify GAGs ifit is successful. 
Then this study wiU investigate the assay characteristics such as， 
1. Unearity, 
2. precision at low, median, and high range of the curve， 
3. within-batch, between-batch, and day-to-day precision, 
4. detection Hmit, 
5. correlation with a standard method, 
6. carryover study, 
1. interference study. 
Reference ranges are set up by measuring samples from refereace populations. The 
capability of the assay to detect the disease is investigated by measuring known patient 




Formic acid sodium salt，tris(hydroxymethyl)aminomethane (Tris)，chondroitin 
sulphate C sodium salt，dematan sulphate sodium salt (chondroitin sulphate B), heparan 
sulphate sodium salt, keratan sulphate sodium salt were purchased from Sigma (St. Louis, 
MO，USA). 1,9-dimethyl-methylene blue was bought from Aldrich Chemical Company 
gVfilwaukee, WI, USA). Formic acid and absolute ethanol were bought from E. 
Merck(64271 Darmstadt, Germany). Serum bovine albumin was brought from Othro-
Diagnostic (Raritan, NJ，USA). 
3.2 Stock solution 
Solution A—DMB was prepared by dissolving 34.8mg in 5ml 95% ethanol. 
Solution B~~Formate buffer(55mmoyL) was prepared by mixing 3.74g sodium formate 
with distilled water and 2ml formic acid and diluted to lL distiUed water. 
Solution C~4t was prepared by mixing 5ml solution A with 995ml solution B’ The final 
concentration ofDMB was lOOjamcM>，formate buffer 55mm‘，pH3.3. 
Sohition D-Tris(hydroxymethyl)-aniinomethane (2moLTL) was prepared by dissolving 
242.2g Tris in lL distiUed water. 
3.1 Stock standards 
Chondroitin sulphate(CS) was prepared by dissolving lmg CS in 10ml distiUed 
water. Dermatan sulphateODS), Heparan sulphate(HS) and Keratan sulphate(KS) were 
similarly prepared. The concentration ofthe four standard solutions were lOOmgA：>. 
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3.4 Working standards 
Working standard solutions of CS, DS, HS and KS (80, 60, 40, and 20 mg/L) 
were prepared by diluting the stock standards appropriately. 
3.5 Worktng DMB solution 
Freshly prepared working DMB solution(DMB concentration: 30^moyL, Tris 
buffer 02moVL, pH8.8) was prepared by mixing 5.5ml of solution B，3 .5ml of solution C 
and 1 ml of solution D. 
3.6 Instruments 
Gitford Response UV-VIS spectrophotometer was from Gilford Mstrument 
Laboratories(Oberlin, OH, USA). Cobas Bio Centrifugal Analyzer was from Hofifinann-La 
Roche (Basle，Switzerland). Hitachi Automatic Analyzer Model 911 was from Hitachi Ltd 
(Tokyo, Japan). 
3J Statistics 
Analysis of variance(ANOVA) was used to check for Hnearity between the curves 
of DMB-GAG reaction. Significance level was set at 0.05. Student t-test was u s ^ to 
check for sex difference in reference range study. Significance level was set at 0.05. Mann 
WWtney test was used to test for significance difference between sex in the same age 
groups. The refoence range was obtained by ranking the data and taking values between 
2.5也 percentiles to 97.5*^  percentiles. Other statistical methods such as mean, standard 
deviation, coefficient of variation were analyzed by personal computer package，Excel 
version 5 (Microsoft Corporation, USA). 
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3.8 Urine samples 
Li this study, urine samples of apparent healthy Chinese subjects were collected 
from neonates in hospital nursery wards, laboratory staff, secondary school children for 
check-up, patients in the out-patient department to estabHsh the reference range. Urine 
samples of mentally retarded patients were from a care home in the Caritas Medical 
Center. Urine samples of MPS patients were from the Prince of Waies Hospital. MPS 
patients were diagnosed on the basis of clinical symptoms and enzyme deficiencies in 
leukocytes and/or fibroblasts. All the urine specimens were either analyzed promptly or 
stored at -70�C until assay. 
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4. Methods 
4A Studies on spectral characteristics 
4.1.1 Spectrum ofDMB 
Working DMB solution was freshly prepared. The solution mixture was scanned 
over the wavelength range of 450-800mn in a Gilford Response UV-VIS 
spectrophotometer. 
4.1.2 SpcGtra ofDMB-GAG products 
80 i^l of60mgyl. CS was added to 1ml offreshly prepared DMB working solution 
and mixed. The solution was added to the cuvette ofthe spectrophotometer immediately. 
A ^ectmm was obtained by scanning the solution over the wavelength range of 450-
800mn. Similarly the spectra of DMB-DS(DS, 70mg/L), DMB-HS(HS, 80mg^) and 
DMB-KS(KS, 50mg/L) were obtained. 
4.2 Studies on stability 
4.2.1 Stability ofDMB dye in assay condition 
Xhe stabiUty of the DMB working solution was investigated in a Cobas Bio 
Centrifugal Analyzer. The absorbance of the pure dye at wavelength of 593nm was 
xnomtored for 5 minutes at an interval of 10 seconds. The instrument settings for Cobas 
Bio were given in appendix 1 
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4.2.2 Stability of DMB-GAG products in assay condition 
The stabiUty ofthe DMB-GAG reaction products was studied using the Cobas Bio 
Centrifugal Analyzer. 20p,l ofa 60mg/L ofCS working solution were added to the cuvette 
rotor of the analyzer. After an initial 10 seconds incubation time, the absorbance was 
measured at 593nm for 5 minutes at an interval of 10 seconds. Similarly the stability of 
DMB-DS, DMB-HS and DMB-KS were also studied. The instrument settings for Cobas 
Bio was the same as given in appendix 1 except that sample volume was 20fil and 
incubation time was lOs. 
4.3 Linearity studies 
4.3.1 Linearity ofDMB dye 
Different concentrations of DMB solution were obtained by making appropriate 
dilutions of buffer solution B with D according to the ratio shown in table 4.1. The 
absorbance ofthe different concentrations ofDMB solution was monitored in the Cobas 
Bio Centrifugal Analyzer. The instrument settings for Cobas Bio were given in appendix 2. 
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Table 4.1 Preparation ofDMB solutions 
Solution B, Solution C, Solution D， Concentration of DMB 
ml mJ n^ in final mixture (^imol/L) 
0 “ 9.0 1.0 一 90 
2.0 7.0 l.Q 70 
4.0 5.0 1.0 50 
4.5 4.5 1.0 45 
5.0 4.0 1.0 40 
5.5 3.5 “ 1.0 35 
6.0 “ 3.0 1.0 ~ 30 
6.5 2.5 1.0 25 — 
7.0 2.0 1.0 20 
7,5 1.5 1.0 15 
8.0 1.0 1.0 10 
9.0 0 1.0 0 
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4.3.2 Linearity of GAG assay 
Standard solutions of CS，DS, HS and KS (80，60，40，20，and Omg/L) were 
aUowed to react with working DMB solution. The reaction was monitored in the Cobas 
Bio Centrifugal Analyzer using the same instrument settings as given in appettdix 2 except 
that sample volume was 20\jd. The change in absorbance (AA) was plotted against the 
concentration of GAGs. 
4.4 Detection limit 
Detection limit was determined by assaying a saline sample(zero concentration of 
GAG) for 30 times. The mean AA and standard deviation were calculated. The mean plus 
3SD ofAA value was calculated and the corresponding lower detection limit in mg/L was 
read from the caUbration curve of the assay. 
4.5 PfBCi$ion study 
4.5.1 Within-run precision 
Quality control samples were prepared by spiking known amounts ofHS in a urine 
sample of low GAG concentration to make a high control (about 45mg/L) and a low 
control (about lOmgA )^. The GAG concentrations of 20 consecutive cups ofthe 2 levels 
of controls were determined in the Cobas Bio Centrifugal Analyzer. The mean and 
standard deviation for each level were calcukted. 
4.5.2 Between-day precision 
The high and low controls prepared in section 4.5.1 were assayed each day for 20 
days to determine the between-day precision. 
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4.6 Interference study 
4.6.1 Haemoglobin 
Haemoglobin from washed erythrocytes was lysed by distilled water to give a 
concentration of lOg/L. Other concentrations of the haemolysate were obtained by further 
dilution of this solution with appropriate amount of distiUed water. Equal volume of 
known concentration ofhaemolysate was added to equal volume ofHS standard solutions 
to make a final haemoglobin concentration ranging from 0 to 5g/L and a GAG 
concentration of 20mg/l>. The samples with and wHhout haemotysate addition were 
assayed using working DMB solution. The differences in concentration were calcukted. 
4.6.2 Protein 
The influence ofprotein on the DMB assay was studied by adding protein to the 
HS standards and urine samples. Equal volume of known concentration (e.g. lOg/L) of 
serum bovine albumin was added to equal volume ofHS standard solutions to make a final 
protein concentration from 0 to 5g/L and a GAG concentration of 35mg/L. The apparent 
concentration ofsamples with and without protein addition in pairs was determined using 
DMB sohition. The difference in concentration was calculated. 
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4.7 Recovery study 
HS standard solutions (e.g. 10，25 and 50mga.) were added to equal volume o fa 
urine sample. Same volume ofdistilled water was added to the urine sample to provide a 
baseHne sample. GAG concentration in the test and baseline samples were analyzed in 
tripUcates within-batch. The recovery ratio was calculate as foUows: 
% recovery=2X(Rtest-Rbase)/C«tandardX100 
where Rtest= result of the test sample 
Rfcase=result of the baseline sample 
Cstandani= Conccntration of standard 
4.8 Correlation study 
The new DMB method was compared with the conventional procedure of 
CPC/Carbazole reaction(48). Urine samples extending over the range of nonnal and 
pathological GAG concentrations were analyzed by both methods. Forty urine samples 
were coUected from normal individuals and from MPS patients. The results were 
eqrressed in relation to creatinine concentration of the urine samples. Carbazole assay was 
performed as described by Pennock(5) and is routinely used in the Department of 
Chemical Pathology at the Prince ofWales Hospital. 
PAGE 34 
4.9 Automated measurement of urinary GAG 
Urinary GAG was measured in the Cobas Bio Analyzer using instrument setting as 
given in appendix 2 except that sample volume was 20pl and standard concentrations were 
HS 20,40，60 mgfL. Urinary creatinine was measured by kinetic Jaffe reaction in a Hfitachi 
911 Analyzer using urinary mode and BM-cfas standard. All results were expressed in mg 
GAG/mmol creatinine ratio. 
4.10 Reference range 
Apparent healthy Chinese subjects were recruited from neonates in hospital 
nursery wards, laboratory staff, secondary school students for check-up, patients in out-
patient department. All the subjects were checked to have no clinical history ofrenal and 
liver diseases, nor inherited disorders. Untimed urine specimen were coUected from the 
reference subjects and the GAG content were measured. Then Reference range was 
obtained by partitioning the reference subjects into a number of age groups according to 
de Jong el at(6); 
• 0~~5 mcsirdis 
• 6 — 1 2 months 
• 13~~23 months 
• 2~~3 years 
• 4^ "^^ 5^ years 
• 6"~7 years 
攀 8"^ "^ 9 years 
• 1 0 ^ 1 4 years 
• 15~~19 years 
• > 2 0 years 
GAGs excretion is age dependent. Excretion was highest in neonates and 
decreased with age. Hence more partitions were found in young children. 
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4.11 GAG in mentaUy retarded patients 
Urine samples from a population of mentally retarded patients in Caritas Medical 
Center were analyzed for their urinary GAG excretions. The result was expressed in 
amount of GAG in relation to urine creatinine excretion, fedividual result was then 




5.f Studies on spectral Characteristics 
5.1.1 DMB Spectrum 
The spectrum of pure DMB dye was shown in figure 5.1. The pure dye had two 
absorption peaks at 593 and 649nm. 
5.1.2 Spectra ofDMB-GAG products 
The spectrum of pure DMB dye and the spectra of the DMB-CS, DMB-DS, 
DMB-HS and DMB-KS products were shown as a composite in figure 5.2. Each DMB-
GAG spectrum of the had three peaks: the first peak belonged to the DMB-GAG 
complex; the second and the third peaks belonged to the DMB dye. The absorbance 






Table 5.1 Absorption maxima ofDMB-GAG products 
GAG First peak, nm Second peak, nm Third peak，nm 
CS 527.5 594 650 
DS 530.5 593.5 649 
HS 540.5 593 650 
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Figure 5.1 Spectrum of DMB Dye PAGE 39 
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Figure 5.2 Spectra of DMB and DMB-GAG complex PAGE 40 
% 
The absorption maxima of the DMB-GAG products ranged from 528-541nm. The 
absorption peaks corresponding to the pure DMB solution were found to be 593-594 and 
649-650nm in aU the DMB-GAG reaction mixtures. These results showed that the DMB-
GAG absorption peaks varied with the type ofthe GAGs. However，the absorption peaks 
corresponding to DMB dye remained at the same wavelengths. It is not desirable to assay 
GAGs using the first absorption peak of the complexes as the peak wavelength varies with 
the different kind of GAGs. It is better to assay the GAGs by monitoring the reaction at 
one of the two absorption peaks of the DMB dye. 
n 
The changes of absorbance at the 3 absorption peaks for the DMB-DS reaction � 
f 
w ^ plotted against DS concentration (Figure 5,3). The 593nm gave a greater response \ 
«1 
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5.2 Studies on stability 
5.2.1 Stability ofDMB dye in assay condition 
The change ofabsorbance against time for DMB dye was shown in figure 5A The 
absorbance at 593nm remained unchanged for at least 300 seconds. 
5.2.2 Stability ofDMB-GAG reaction mixture in as$ay condition 
The change of absorbance of DMB-CS against time was shown in figure 5.5a. It 
showed that the absorbance of the reaction mixture at 593nm remained unchanged for at 
l^st 300 seconds. Similar absorbance change was also observed for DNffi-DS，DMB-HS 
and DMB-KS as shown in figure 5.5b-5.5d. A time interval of 40 seconds was chosen to 
assay the GAGs. 
5.3 Uneariiy studies 
5.3.1 Linearity ofDMB dye 
The absorbance of the different concentrations ofDMB solutions was monitored in 
the Cobas Bio Centrifugal Analyzer. Figure 5.6 showed the change in absorbance versus 
DMB concentrations. It was found that the curve was Hnear up to the DMB concentration 
of 40^uno^L. DMB concentration of 35fjjnol/L was used in the GAG assay. Linearity 
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5.3.2 Lmearity of GAG assay 
The AA was plotted against the concentration of GAGs. Figure 5.7 depicted AA 
ag^s t various concentrations of CS, DS, HS and KS. It was found that AA was linearly 
related to the concentration ofCS，DS, HS and KS up to 70 mg/L. Figure 5.7 showed that 
the four linearity curves had similar slopes for GAG concentration up to 70mg/L. The 
slopes (table 5.2) of the four standard curves were calculated and significant difference 
were tested by ANOVA. The slopes were found to be not significantly different. Similarly 
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Table 5.2 The slopes ofthe DMB-GAGs curves 
GAG Slope 
1鍵 run r ^ n m 3^mn 4^run 5^mn 
CS 0.0102 0.0101 0.0102 0.0101 0.0099 
DS 0.0101 0.0098 0.0106 0.0100 0.0093 
HS 0.0103 0.0104 0.010 0.0101 0.0104 
KS 0.0102 0.0102 0.0103 0.0103 0.0102 
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5.3.3 Detection limit 
A blank sample was run 30 times. The mean AA was 0.103 and the standard 
deviation was 0.265. The corresponding lowest detection limit was read from the 
caHbration curve and was found to equal to 0.8mg/L. 
5.4 Precision study 
The within-run and between-run precisions for the low and high controls were 
shown on table 5.3, The coefficient of variation was better than 7%. 
I j 
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Table 5 .3 Result of precision study 
Within-run Between-day 
Control level Low High Low ffigh 
mean(mg/L) 11.4 47.7 12.2 48.7 
SD 0.5 1.1 0,8 1.3 




5.5 Interference study 
5.5.1 HaemogIobui 
GAG concentration (mg/L) was measured in aqueous solutions of HS after 
addition of haemolysate. The haemoglobin concentrations varied from 0 to 5g/L. The 
results were shown in table 5.4. Haemoglobin did not interfere with the new DMB assay 
for concentration up to 5gfL. 
$.5,2 Protein 
GAG concentration (mg/L) was measured in aqueous solutions of HS after 
addition ofserum bovine albumin. The protein concentrations varied from 0 to 5g/L. The 
result was shown in table 5.5. There was no interference with the new DMB assay by 
albumin concentration up to 5g/L. 
5.6 Recoverystudy 
The result was given in table 5.6. Concentration of the HS standard ranged from 
10 to 50mg/L. Urinary GAG concentration was 8.4 mg/L. The mean percentage of 
recovery was 100.57%. 
5.7 Correlation study 
Results ofthe comparison between the new DMB method and the CPC/Carbazole 
reaction for forty urine samples were shown in figure 5.8. The present method correkted 
well with the CPC/Carbazole assay for GAG. Linear regression analysis gave a correlation 
coefficient(R) of0.929. After Deeming's correction, the Unear regression equation can be 
expressed as: [new DMB]- 0.87[CPC/Carbazolel+4.69 
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Table 5.4 Interference study by haemoglobin 
Measured HS Concentration(mg/L) 
Haemolysate 0.0 0.1 0.2 0,3 0.4 0.5 
concentration (g/dL) 
sample 1 0.0 ~ 0.0 0.6~ 0.5 “ 0.0 —0.2 
sample2 11.2 ~ l O . S 11.0一 11.1 — l l O 10.7~ 
sample 3 18.2 —18.0 19.4— 20.0 “ 19.4 ~ n A ^ 
sample4 40.2 40.1 39.9 40.2 40.1 4 1 . 6 ， • 
Table 5.5 Literference study by protein 
Measured HS Concentration (mg/L) 
serum bovine • 1 2 3 4 5 
albumin (g/L) 
Sample 1 0.0 — 0.0 0.0 0.5 — 0.0 0.2 
Sample 2 18.6 —18.7 17.7 17.2 18.0 一 17.0 
Sample 3 30.7 31.0 29.9 2 9 . 6 ~ 30.1 29.9 
Sample 4 59.7 59.2 60.1 58.4 58.6 58.0 
Table 5.6 Recovery study 
Rbaae Rtest 
Concentration in mgfL ]^ ^ 50 
first run 8.3 ~U3 20.7 33.6 
second mn 8.4 13.4 2 o T ^ 33.9 — 
thirdrun — 8.6 13.6 21.0 33.8 """ 
mean 8.4 13.4 20.9 “ 33.7 




























































































































5-8 Reference range 
A group of 546 (male 285, female 261) apparently healthy Hong Kong Chinese 
subjects with age ranging from 1 day to 70 years had been recruited in the reference 
population. Table 5.7 gave the reference value of urinary GAG/creatinine ratio as a 
fiinction of age and sex. The GAG/creatinine ratio was not significantly different between 
the sexes (stendent t-test, P>0.05). 
The reference values for the new DMB assay were age dependent (figure 5.9). The 
change in GAG as a fimction of age was greatest in young age groups. M those older than 
20 years, GAG content was nearly constant. In view the non-Gaussain distribution in each 
age-group, non-parametric method was used to derive the reference ranges(table 5.8). 
5,9 GAG In ment0Uy Fetanied patients 
Urine samples from 295 mentaUy retarded patients Hving in Caritas Medical center 
were coUected. Urine GAG was measured and the result was expressed in amount of 
GAG in relation to urine creatinine excretion. Figure 5.10 showed the GAG excretion 
against age. 35% of these patients had GAG/creatinine above the 95% upper interval of 
the general population at the same age groupOP<0.05, Mann Whhney test). One of the 
samples had GAG content over 70mg/mmol creatinine. 
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Table 5.7 Reference values of urina^ GAG/creatinine ratio measured by the new DMB 
assay according to sex and age 
Male I Female 
Age N Median Range N Median Range 
mg/mmol mg/mmoI mg/mmol mg/nmiol 
0—5 months 50 37.8 23.1-50.5 70 38.0 24.1.52.1 
6—12 months 9 18.9 15.9-22.5 12 20.1 16,5-24.0 
13—23 m o n t h s " ~ n I s 7 ~ 14.8-22.1 14 18.5 15.9-22.2 
2—3 years I i rT7 12.1-22.1 16 17.5 12.3-21.9 
“ 4 — 5 years ^ m “ 10.5-19.7 27 15.1 10.8-19.5 
MMMM**MMMaMMwMMMMMMMMwwMMMi^M 0m^mm^m^tmimmmmm mmmmm^^mm^mtmm^mm^mrn^t^ mmmmm^mmmmmmt^^^^mrnmm^mmi^^^—^m m^mtm^mmrrnmmmi^m^ m1^^mm^mmm^mmmmmm^mmm0t10^ MHMMMm*Mw^MWMwMMMMMM#MM 
6—7 years 18 13.7 10.2-16.0 14 13.9 10.1-16,9 
~ 8 — 9 years U u l “ 9.M3.2 18 12.0 9.6-13.5 
10_-14 years 4 ^ 5.5 2.9-8.1 37 6.9 3,5-9.1 
15_19years s i P 3.1 1.2-5.0 42 2.9 h5A.9 
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Table 5.8 Reference range of urine GAG/creatinine ratio by non-parametric method (2.5也 
percentile to 97.5 也 percentile) 
GAG/creatinine 
Age mg/mmol creatinine 
(2.5^-97.5^ percentile) 
0—5 months 20.S—56.0 
6—12 months 15.9—24.5 
13—23 months 15.6—21.1 
2—3 years 14.6—20.6 
4—5 years 10.5—20.0 
6>-7 years 9.1—16.1 
a~9years 9.0—13.5 
_ - .. - - . .- . - •_i^I I. • I I ‘ _ •丨 I ‘丨丨 I f 
i a -14years 3.3—10.7 j 
• 丨 丨 I ‘ I ‘ I I ‘ " ‘ i 
15—19 years 1.4—5,2 
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Some degree of successftil treatment ofMPS has been achieved recently(19, 20， 
22). An efficient，low-cost screening method for MPS becomes essential. In recent years, 
direct dye binding methods for GAG quantitation appeared in the Uterature, such as 
AB(50), DMB(l,51), DMB-TRIS(49) methods. They provided a direct quantitation of 
urinary GAGs, doing away with the precipitation step. Obviously these methods were 
simpler to perform and faster to obtain results. In the evaluation of the anafytical 
performance ofAB and DMB, de Jong et al (49) found that DMB had a higher sensitivity 
than AB in the differentiation ofnormal persons from MPS patients. They concluded that 
DMB assay was a better screening method for MPS than AB assay. 
The DMB assays reported in the Uterature monitored the increase of absorbance of 
the DMB-GAG complexes at about 530mn. The spectral characteristics ofdifferent DMB-
GAG complexes were investigated in this study. The absorption maxima of the complexes 
were found to vary between 528-541nm, Similar finding was obtained by Stone et al (4). 
Measurement of products at one wavelength would lead to inaccurate results depending 
on the relative composition of differeat GAGs in the samples. The measurement of the 
complexes at 530nm would also have spectral interference by haemoglobin. However the 
spectrum ofthe pure DMB dye had two peaks: 593 and 649 nm. An alternative solution 
would be to measure the decrease in absorbance at either one of the peak wavelengths of 
the pure dye. This was the basic principle of the estabHshed new DMB method in this 
project. 
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The DMB-DS reaction at the three absorption peaks were investigated. The 
decrease in magnitude ofabsorbance ofthe pure dye at 647ran was greater than that ofthe 
increase in absorbance of the complex at 520nm. But the response at wavelength 593nm 
was even Mgher. These observations agreed with the findings by Stone et al (4). 
The original DMB assay used formic acid as bufFer(3). However it was found to 
have interference by urinary protein and haemoglobin(67). An improved DMB assay was 
developed by de Jong (6) which involved the use of a tris-bufFer. Such modification was 
ciaimed to remove the interference by protein. Merference by haemoglobin could be 
removed by including a blank measurement. 
This study attempted to measure GAGs at 593nm using a tris buffer. The DMB 
pure dye and the reaction complexes of DMB-GAG were found to be stable for up to 
300s. There were no significant difference in reactivity of the four GAGs towards the 
DMB dye. This observation agreed with the finding by Whitley et al(3). 
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6,1 Analytical Performance 
The new DMB assay was automated in a Cobas Bio autoanalyzer. The sample 
volume used in this assay was 20p,l. The tesponse of the reaction was monitored at 
wavelength 593 for 40s. The lowest detection limit was 0.8mg/L and the Unearity range 
was found to be up to 70mg/L using a DMB concentration of 35 .^moVL. Sensitivity 
analysis showed that this method gave an absorbance change of 0.285A per iig ofGAG in 
the reaction ceU as compared to de Jong et al (49) 0.242A per \ig and Whitley et al (3) 
0.05A per ug. Hence, this new method was more sensitive and was expected to have 
improved precision. Albumin and haemoglobin did not interfere with this assay up to 5g/L 
and 5g/L respectivdy. These findings agreed wrth those by de Jong et aK6). 
The new DMB assay was compared with the conventional CPC/Carbazole 
method. Deeming's correction was applied for the correlation study to take account ofthe 
assay uncertainty of the CPC/Carbazole method. The corrdation coefficient was 0.929 
and the Unear regression equation was [new DMB]= 0.87[CPC/Carbazok]+4.69. Similar 
finding was obtained by a study(66) which showed that the DMB assay correlated weU 
with the CPC/Carbazole test(r=0.837). 
The new DMB method gave more precise results than the conventional method. 
Within-run imprecisions were 4.5% and 2.4% at 11 and 48 mg/L respectively. Between-
batch imprecisions were 6.5% and 2.6% at 11 and 48 mg/L respectively. The 
CPC/Carbazole method usually had a precision of over 10% at these levels. Similar 
findings were obtained a study by de Jong et aI(6). The imprecision oftheir DMB assay 
varied from 2% to 7% at GAG between 22-72mg/L. This study demonstrated a recovery 
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from 99% to 101%. It was better than anther study(66), which showed a recovery of71% 
to 107%. 
The new DMB method was simple and fast to measure the urinary GAG. It 
required only about 5 minute to assay a batch of 24 samples. Smail sample volume (20pJ 
in this assay) was certainly an advantage to screen samples from neonates. The 
CPC/Carbazole method required large sample volumes (2-10ml urine) which could not be 
routinely collected from infants. It could be automated in other modem automatic 
chemistry analyzer. However, in many modem chemicai analyzers, discrete filters were 
usuaUy employed. They might not have a filter for 593nm. Li view of the greater response 
at 593nm as seen in this study，a nearby wavelength could be used instead without greatly 
affecting the performance of the assay. 
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6.2 Clinical performance 
6.2.1 Reference population 
Urine for analysis could be collected as a 24-hour urine sample or as a random 
urine. 24-hour urine samples were not convenient and incomplete coUection could lead to 
erroneous result. Spot urine samples were used because it was easy to coUect and could be 
obtained any time from tbe subjects especiaUy infants. The GAGs content in the untimed 
urine samples were measured and expressed in relation to the creatinine excretion. 
Although creatinine excretion varied during a 24-hour period and the GAG/creatinine ratio 
was increased at night(7), both substances were excreted at fairly constant rates during the 
day(0800 to 1800). The GAG/creatinine ratios in samples obtained during this period 
agree reasonably well with those obtained on complete 24-hour coUections{5). Infected 
samples shouM not be used (5). Fresh urine was more appropriate. If analysis could not 
be performed as soon as possible, the samples were best frozen after collection and stored 
at -70"C. 
This study measured spot urine GAG-creatinine ratio from 546 apparently healthy 
Hong Kong Chinese subjects with age ranging from 1 day to 70 years. The reference 
values for the new DMB assay were, as for other DMB assays(5,6), age dependent. The 
GAG/creatinine ratio was not significantly different between the sexes0P>O.O5, student t-
test). The GAG excretion was high in the neonatal period because of the rapid growth rate 
at this time ofHfe. The GAG excretion then decreased with age and leveled off after age 
20. This age dependent reference range was found to be similar to the findings by de Jong 
et al (6). No previous reference range for Chinese subjects was reported in the literature. 
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This was the first estabUshed reference range for Hong Kong Chinese population. 
However, the established reference range in this study was similar to other group of 
studies from western countries(5,6). Reference range from western population could be 
applied to normal Chinese subjects. 
6.2,2 MentaUy retarded patients 
295 subjects were selected from a group of mentaUy retarded patients. These 
patients were living in a care center for the handicapped, mentally retarded patients, 35% 
of these patients had GAG/creatiniae above the 95% upper interval of the general 
population at the same age group(P<0.05, Mann Whitney test). Some of these patients 
and wery high GAG/creatmiae ratio eg, 70mg/tnmol creatinine and they may be 
undiagnosed MPS patients. Confirmation methods such as two dimensional 
electrophoresis or enzyme techniques should be carried out to evaluate these cases. 
This group ofpatients is associated with a failure in physical development. In these 
patients delayed growth or altered metaboUsm may be present. Their physical 
development(eg. bone, cartilage) could be lagged behind their chronological age. Since 
GAG/creatinine ratio is age dependent, it mi^t explain why there were 35% of these 
patients had elevated GAG excretion above the upper reference interval. Probably a 
separate reference range should be estabHshed for these patients. Elevated GAG excretion 
was also found in patients with connective tissue destruction (5). The mentally retarded 
patients recruited in this study might also have these disorders that caused a significant 
higher GAG/creatinine ratio. These results also suggested that there is a need to 
investigate the cause of mentaUy retarded patients in Hong Kong. 
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6.2.3 Suggestion for future studies 
The new DMB assay was only screening test. Elevated results should be confirmed 
by enzymatic technique. The assay was only linear up to 70mg/L. Abnormally high results 
required dilution, hiterference from other substances such as drugs, coloured dyes or 
abnormal metabolites that commonly presented in urine had not been studied. 
Li the present study, only 546 normal subjects were recruited for estabUshing the 
reference range. More reference subjects at different age group could be recruited. Ttey 
were only checked for renal and liver diseases. Many disorders were known to cause 
elevated urinary GAG, such as rickets, malabsorption syndromes, osteomakcia, 
lotkaemia, disseminated lupus erythematosus, rheumatoid arthritis and some rare 
i 
disorders(5). These abnomaHties should be considered in future recruitment of reference 
subjects. Nevertheless, the established reference range was similar to those reported in the 
literature. 
Mei^ally retarded patients were shown to have elevated GAG excretion in this 
study. The causes of such elevation should attract more investigations to see whether a 
separated reference range is needed to be established for the patients in the care home. 
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7. Conctuston 
The new DMB assay was simple and precise for quantitation of GAG contents in 
urine samples. It was found to be free from interference by protein and haemoglobin. 
Good correlation was found with the CPC/Carbazoie method. It gave a higher response 
than the original DMB assay or the DMB-tris assay. 
This assay can be automated in any modem analyzer GAG/creatinine ratio 
decreased significantly with age. But no significantly difference between the sexes was 
found. The sample volume was as little as 20ul, making it possible for screening neonates. 
Mentally retarded patients were shown to have higher GAG content than the general 
population at the same age groups. Further evaluation should be carried out to investigate 
why there was such discrepancy. 
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8. Appendix 
Appendix 1 Instrument settings for DMB stability study: 
-MUCQ — 
_ L _ Units MG/L 
2. Calculation factor 1 
3. Standard 1 concentration 0 
4. Standard 2 concentration 0 
5. Standard 3 concentration 0 
6. Limit 0 
1 _ Temperature (^C) 一 25 
8. Type of analysis 1 
9. Wavelength (nm) 593 
10 Sample volume (pl) 0 
11 Diluent volume (^ il) 0 
12 Reagent volume (M.1) 250 
13 Incubation time (seconds) 0 
14 Start reagent volume (^ il) 0 
15 Time of first reading (seconds) OJ 
16 Time interval (seconds) J^ 
17 Mmober of readings 30 
18 Blanking mode 0 
19 Printoutmode 3 
Appendix 2 Instrument settings for DMB linearity study: 
-MUCO 
1. “ Units MG/L 
2. Calculation factor 1 
3. Standard I concentration 0 
4. Standard 2 concentration 0 
5. Standard 3 concentration _0 
~ 6 . ~ Limit — 0 
7. Temperature (^ C) 25 
S. Type of analysis 1 
9. Wavelength (nm) 593 
10 Sample volume (^ tl) 0 
11 Diluent volume (pJ) 0 
12 Reagent volume (^ 1) 250 
13 Incubation time (seconds) ^ 
14 Start reagent volume (yil) 0 
15 Time of first reading (seconds) 0.5 
16 Time interval (seconds) 40 
17 Number of readings 2 
18 Blanking mode 0 
19 Printout mode 5 
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